Pharmacology News and Research

Latest Pharmacology News and Research

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers

The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.

18 Mar 2010

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.

17 Mar 2010

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACU-4429, an investigational oral treatment for dry age-related macular degeneration (dry AMD).

17 Mar 2010

PAREXEL genotypes over 10,000 potential study participants to identify 400 CYP2D6 poor metabolizers

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has completed a large and complex pharmacogenetics-based early phase study. The study was conducted in a healthy volunteer population of poor metabolizers of Cytochrome P450 2D6 (CYP2D6), an important enzyme involved in the metabolism of drugs. The study monitored the QTc interval following administration of a neurological treatment, which has been shown to have a higher drug exposure in poor metabolizers of CYP2D6.

From Parexel 17 Mar 2010

TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene

A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene. Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix® (clopidogrel) plus aspirin or Effient® (prasugrel) plus aspirin and managed with percutaneous coronary intervention (PCI) following an acute coronary syndrome (ACS) event.

17 Mar 2010

Consumers are becoming more price-sensitive toward brand-name drugs

The results of a new Pharma Insight study released today by Wolters Kluwer Pharma Solutions, Inc., a leading provider of scientific information and analytics to the pharmaceutical and biotech fields, is not exactly what the doctor ordered. The company's annual analysis of the U.S. pharma market suggests that the economy has led to increased patient participation in decisions about prescription drugs.

17 Mar 2010

Key cellular defect in protein synthesis can lead to cancer susceptibility

UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.

17 Mar 2010

Lantheus Medical Imaging announces preliminary data on flurpiridaz F 18 PET MPI agent

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced preliminary data on flurpiridaz F 18 (formerly known as BMS747158), its novel compound in development as a Positron Emission Tomography (PET) myocardial perfusion imaging (MPI) agent. The study of nine patients compared rest-stress flurpiridaz F 18 PET MPI, with rest-stress technetium-99m (Tc-99m) labeled single photon emission computed tomography (SPECT) for the detection and evaluation of coronary artery disease (CAD).

16 Mar 2010

BeaconEquity.com announces investment report featuring NexMed

BeaconEquity.com announces an investment report featuring NexMed Inc. (Nasdaq:NEXM). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

12 Mar 2010

BDNF could someday play significant role in prevention of high blood pressure: Study

Researchers at Oregon Health & Science University's School of Dentistry (www.ohsu.edu/sod) have discovered that nitric oxide is a powerful regulator of a molecule that plays a critical role in the development and function of the nervous system. The finding could someday play a significant role in the prevention and treatment of high blood pressure, which affects about one in three adults in the United States.

12 Mar 2010

Novel mutation in gene encoding ankyrin-B increases risk of type 2 diabetes

Alterations in our response to the taste or smell of food may be another culprit responsible for Type 2 diabetes, according to scientists at Duke University Medical Center who have identified the specific mechanism in human specimens and in mice.

12 Mar 2010

Tel Aviv University investigates cause and effects of SCA syndrome

Sudden Cardiac Arrest syndrome (SCA) is poorly understood, but it's a real danger for the otherwise young and healthy. For no apparent reason, the heart suddenly stops beating, and without treatment death may follow within minutes. It's why some athletes drop dead on the track and why a young man, without any warning, suddenly dies while sitting at his desk.

11 Mar 2010

NIH panel recommends delivery options for women: VBAC or cesarean

An independent panel convened this week by the National Institutes of Health confronted a troubling fact that pregnant women currently have limited access to clinicians and facilities able and willing to offer a trial of labor after previous cesarean delivery because of so-called VBAC bans.

11 Mar 2010

AiDKlinik information system reduces adverse drug interaction numbers

To get life-threatening diseases under control, patients in the intensive care unit usually are administered many medications at the same time. Even for experts, it is difficult to keep track of the variety of possible side effects and interactions.

11 Mar 2010

Promising preliminary results from ProFibrix' Phase II trial of hemostat Fibrocaps

ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the conclusion of the first Phase II trial testing its unique new hemostat Fibrocaps(TM). Promising preliminary data from the European multicenter, open-label trial show compelling safety and efficacy (time to hemostasis) profiles for Fibrocaps, and good performance of the delivery device.

11 Mar 2010

TNS acquires license to Ergothioneine Transporter from University of Cologne

Total Nutraceutical Solutions, Inc. announced that the company has acquired from the University of Cologne, Cologne, Germany, an exclusive license agreement on the invention entitled “Ergothioneine Transporter,” owned by the University.

10 Mar 2010

Bayer's bioequivalence study comparing Adalat XL to Mylan-Nifedipine Extended Release flawed, says Mylan

Mylan today reported that it has identified multiple flaws within a purported bioequivalence study sponsored by Bayer Inc. of Canada. The study compared Bayer's antihypertensive Adalat(R) XL(R) tablets, 60 mg, marketed in Canada, to Mylan's approved generic version, Mylan-Nifedipine Extended Release tablets, 60 mg, marketed in Canada.

10 Mar 2010

New data for BMS747158 to be featured in oral presentation at ACC Annual Scientific Session 2010

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced that new data for BMS747158, the company’s novel drug candidate in clinical development as a Positron Emission Tomography (PET) perfusion imaging agent, will be featured in an oral presentation at the American College of Cardiology 59th Annual Scientific Session taking place March 14-16, 2010 in Atlanta.

10 Mar 2010

Novel protein haditoxin in King Cobra's venom discovered

The King Cobra continues to weave its charm with researchers identifying a protein in its venom with the potential for new drug discovery and to advance understanding of disease mechanisms.

9 Mar 2010

AssureRx Health adds CYP1A2 gene to laboratory-developed pharmacogenetic test

AssureRx Health, Inc., a personalized medicine company focused on pharmacogenetics to aid in the treatment of patients with psychiatric disorders, today announced that it has added a fifth gene, CYP1A2, to its laboratory-developed pharmacogenetic test.

9 Mar 2010

Pharmacology News and Research

Latest Pharmacology News and Research

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

PAREXEL genotypes over 10,000 potential study participants to identify 400 CYP2D6 poor metabolizers

TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene

Consumers are becoming more price-sensitive toward brand-name drugs

Key cellular defect in protein synthesis can lead to cancer susceptibility

Lantheus Medical Imaging announces preliminary data on flurpiridaz F 18 PET MPI agent

BeaconEquity.com announces investment report featuring NexMed

BDNF could someday play significant role in prevention of high blood pressure: Study

Novel mutation in gene encoding ankyrin-B increases risk of type 2 diabetes

Tel Aviv University investigates cause and effects of SCA syndrome

NIH panel recommends delivery options for women: VBAC or cesarean

AiDKlinik information system reduces adverse drug interaction numbers

Promising preliminary results from ProFibrix' Phase II trial of hemostat Fibrocaps

TNS acquires license to Ergothioneine Transporter from University of Cologne

Bayer's bioequivalence study comparing Adalat XL to Mylan-Nifedipine Extended Release flawed, says Mylan

New data for BMS747158 to be featured in oral presentation at ACC Annual Scientific Session 2010

Novel protein haditoxin in King Cobra's venom discovered

AssureRx Health adds CYP1A2 gene to laboratory-developed pharmacogenetic test

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Pharmacology News and Research

Latest Pharmacology News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in